Hedros Bio Inc

Hedros Bio is a biotechnology company focused on revolutionizing disease control in aquaculture by utilizing bacteriophages to combat bacterial pathogens. The company identifies and isolates specific phages that target harmful bacteria, such as those responsible for Acute Hepatopancreatic Necrosis Disease (AHPND) in shrimp, while leaving beneficial bacteria unaffected. To optimize these treatments, Hedros Bio employs a proprietary, AI-driven software platform called PhageChooser, which analyzes large datasets to design custom bacteriophage cocktails tailored for precise and effective disease management. This technology provides an environmentally friendly alternative to traditional antibiotics, aiming to improve the health of aquatic ecosystems and support sustainable seafood production.

By replacing conventional antibiotic use with targeted phage therapy, Hedros Bio helps aquaculture producers mitigate the economic and environmental impacts of bacterial outbreaks. This approach is designed to preserve the delicate balance of aquatic environments while ensuring higher survival rates for aquatic species. Through its multidisciplinary team of scientists and experts, the company works to integrate these sustainable biotechnological tools into global aquaculture operations, addressing the growing demand for safer and healthier seafood while promoting long-term industry sustainability.